Paroxysmal nocturnal haemoglobinuria treatment with eculizumab is associated with a positive direct antiglobulin test
Britta Höchsmann(German Red Cross), Hubert Schrezenmeier(German Red Cross), Willy A. Flegel(National Institutes of Health), Sabine Kaiser(Universität Ulm), I. von Zabern(Universität Ulm), R. Leichtle(Universität Ulm)
Cited by 41
Related Papers
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
|New England Journal of Medicine|2006|1.3k
Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria
|Blood|2007|653
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria
|Blood|2007|578
Molecular Basis of Weak D Phenotypes
|Blood|1999|336
Molecular Basis of Weak D Phenotypes
|Blood|1999|331